Candid Therapeutics and EpimAb Biotherapeutics Join Forces
SAN DIEGO & SHANGHAI-- Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology pioneer focusing on T-cell engagers for autoimmune diseases, has entered into a strategic collaboration with EpimAb Biotherapeutics, Inc. (“EpimAb”) a clinical-stage biopharmaceutical company known for developing multi-specific antibodies aimed at addressing urgent medical needs. This partnership aims to discover and develop novel T-cell engager candidates for various autoimmune indications.
Collaboration Highlights
Dr. Ken Song, the Chairman, President, and CEO of Candid, expressed enthusiasm about the partnership, stating, “EpimAb’s team has impressed us with their scientific expertise and antibody design capabilities. We are excited to partner with EpimAb as we broaden our pipeline of novel TCEs for autoimmune indications.”
Innovative Approaches in Biotech
Echoing this sentiment, Dr. Chengbin Wu, CEO and founder of EpimAb, stated, “We are excited to enter this partnership with Candid, a company with the leadership and resources to realize the full potential of TCEs in autoimmune indications. We are proud of the versatility of our proprietary bispecific and TCE platforms, and this partnership provides further validation of our approach.”
Financial Aspects of the Agreement
Under the terms of their agreement, EpimAb will receive an upfront payment alongside development and sales milestones that could exceed $1 billion, assuming several drug candidates successfully progress through commercialization. Additionally, Candid will secure royalties on net sales. Candid has been granted exclusive worldwide rights to develop and commercialize programs discovered during this collaboration.
Company Insights
About Candid Therapeutics, Inc.
Candid Therapeutics is establishing itself as a leader in advancing T-cell engagers aimed at B-cell depletion for autoimmune diseases. This innovative company is currently advancing two lead B-cell depleting TCE antibody drug candidates. Their goal is to explore the potential of TCEs broadly across various autoimmune diseases by targeting different B-cell protein targets and evaluating diverse levels of B-cell depletion. Founded in 2024 and headquartered in San Diego, Candid is spearheaded by a team of seasoned executives with a proven history of advancing programs through development, supported by a notable group of premier life science investors.
About EpimAb Biotherapeutics, Inc.
EpimAb Biotherapeutics is at the forefront of developing multi-specific antibodies, boasting a remarkable array of in-house research and technological capabilities. Their proprietary platforms, such as the FIT-Ig and MAT-Fab bispecific platforms, empower EpimAb to generate a unique pipeline of transformative preclinical and clinical assets designed to benefit cancer patients. Their innovative approach positions them well to contribute significantly to the field.
Frequently Asked Questions
What is the focus of the collaboration between Candid and EpimAb?
The collaboration aims to discover and develop novel T-cell engager candidates targeting autoimmune diseases, leveraging each company's expertise.
What are T-cell engagers (TCEs)?
T-cell engagers are engineered proteins that direct T-cells to target and destroy specific cells, including those involved in autoimmune conditions.
What financial terms were discussed in the agreement?
EpimAb could receive over $1 billion in payments, contingent on the advancement of multiple drug candidates, along with royalties on net sales.
Who leads Candid Therapeutics?
Candid Therapeutics is led by Dr. Ken Song, who serves as the Chairman, President, and CEO, backed by a skilled executive team.
Where is EpimAb Biotherapeutics headquartered?
EpimAb Biotherapeutics is a clinical-stage biopharmaceutical company with advanced research facilities and operations focusing on innovative therapies for unmet medical needs.
